These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

37 related articles for article (PubMed ID: 21694620)

  • 1. Therapeutic Drug Monitoring of Olanzapine: Effects of Clinical Factors on Plasma Concentrations in Psychiatric Patients.
    Ansermot N; Vathanarasa H; Ranjbar S; Gholam M; Crettol S; Vandenberghe F; Gamma F; Plessen KJ; von Gunten A; Conus P; Eap CB
    Ther Drug Monit; 2024 Jun; ():. PubMed ID: 38833576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Management of treatment resistance-Treatment-resistant schizophrenia].
    Wagner E; Borgwardt S; Hasan A
    Nervenarzt; 2024 May; 95(5):423-431. PubMed ID: 38319320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment resistance in psychiatry: state of the art and new directions.
    Howes OD; Thase ME; Pillinger T
    Mol Psychiatry; 2022 Jan; 27(1):58-72. PubMed ID: 34257409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Compilation of Serum Concentrations of 12 Antipsychotic Drugs in a Therapeutic Drug Monitoring Setting.
    Jönsson AK; Spigset O; Reis M
    Ther Drug Monit; 2019 Jun; 41(3):348-356. PubMed ID: 31025986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrating rare genetic variants into pharmacogenetic drug response predictions.
    Ingelman-Sundberg M; Mkrtchian S; Zhou Y; Lauschke VM
    Hum Genomics; 2018 May; 12(1):26. PubMed ID: 29793534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Pilot Study of the Usefulness of a Single Olanzapine Plasma Concentration as an Indicator of Early Drug Effect in a Small Sample of First-Episode Psychosis Patients.
    Zabala A; Bustillo M; Querejeta I; Alonso M; Mentxaka O; González-Pinto A; Ugarte A; Meana JJ; Gutiérrez M; Segarra R
    J Clin Psychopharmacol; 2017 Oct; 37(5):569-577. PubMed ID: 28796022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex differences in plasma clozapine and norclozapine concentrations in clinical practice and in relation to body mass index and plasma glucose concentrations: a retrospective survey.
    Anderson SG; Livingston M; Couchman L; Smith DJ; Connolly M; Miller J; Flanagan RJ; Heald AH
    Ann Gen Psychiatry; 2015; 14():39. PubMed ID: 26583040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipsychotic therapeutic drug monitoring: psychiatrists' attitudes and factors predicting likely future use.
    Law S; Haddad PM; Chaudhry IB; Husain N; Drake RJ; Flanagan RJ; David AS; Patel MX
    Ther Adv Psychopharmacol; 2015 Aug; 5(4):214-23. PubMed ID: 26301077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of Sertraline Co-Administration on the Pharmacokinetics of Olanzapine: A Population Pharmacokinetic Analysis of the STOP-PD.
    Davies SJ; Mulsant BH; Flint AJ; Meyers BS; Rothschild AJ; Whyte EM; Kirshner MM; Sorisio D; Pollock BG; Bies RR
    Clin Pharmacokinet; 2015 Nov; 54(11):1161-8. PubMed ID: 25971243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms.
    McCutcheon R; Beck K; Bloomfield MA; Marques TR; Rogdaki M; Howes OD
    J Psychopharmacol; 2015 Aug; 29(8):892-7. PubMed ID: 25788157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine.
    Tsuda Y; Saruwatari J; Yasui-Furukori N
    BMJ Open; 2014 Mar; 4(3):e004216. PubMed ID: 24595134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olanzapine long-acting injection: insights from an early case series in the UK.
    McGlennon D; Bushe CJ
    Ther Adv Psychopharmacol; 2012 Oct; 2(5):189-93. PubMed ID: 23983974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients.
    Bergemann N; Frick A; Parzer P; Kopitz J
    Pharmacopsychiatry; 2004 Mar; 37(2):63-8. PubMed ID: 15048613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olanzapine and risperidone plasma concentration therapeutic drug monitoring: A feasibility study.
    Law S; Gudbrandsen M; Magill N; Sweetman I; Rose D; Landau S; Flanagan RJ; David AS; Patel MX
    J Psychopharmacol; 2015 Aug; 29(8):933-42. PubMed ID: 26040903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication.
    Gex-Fabry M; Balant-Gorgia AE; Balant LP
    Ther Drug Monit; 2003 Feb; 25(1):46-53. PubMed ID: 12548144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olanzapine: a systematic review and meta-regression of the relationships between dose, plasma concentration, receptor occupancy, and response.
    Bishara D; Olofinjana O; Sparshatt A; Kapur S; Taylor D; Patel MX
    J Clin Psychopharmacol; 2013 Jun; 33(3):329-35. PubMed ID: 23609380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response.
    Mauri MC; Volonteri LS; Colasanti A; Fiorentini A; De Gaspari IF; Bareggi SR
    Clin Pharmacokinet; 2007; 46(5):359-88. PubMed ID: 17465637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma olanzapine in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1999-2009.
    Patel MX; Bowskill S; Couchman L; Lay V; Taylor D; Spencer EP; Flanagan RJ
    J Clin Psychopharmacol; 2011 Aug; 31(4):411-7. PubMed ID: 21694620
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.